2142.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 03:44):

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas...

Stats
Dagens volum	85 000.00
Gjennomsnittsvolum	1.31M
Markedsverdi	978.20M
EPS	HKD0 ( 2024-03-27 )
Neste inntjeningsdato	( HKD0 ) 2024-06-06
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	5.52
ATR14	HKD0.0100 (0.79%)

Volum Korrelasjon

Lang: -0.12 (neutral)

Kort: 0.00 (neutral)

Signal:(51.618) Neutral

HBM Holdings Limited Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

HBM Holdings Limited Korrelasjon - Valuta/Råvare

-0.75
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.83
( strong negative )

0.00
( neutral )

0.77
( moderate )

HBM Holdings Limited Økonomi

Annual	2023
Omsetning:	HKD89.50M
Bruttogevinst:	HKD87.47M (97.73 %)
EPS:	HKD0.0300

FY	2023
Omsetning:	HKD89.50M
Bruttogevinst:	HKD87.47M (97.73 %)
EPS:	HKD0.0300

FY	2022
Omsetning:	HKD40.66M
Bruttogevinst:	HKD40.53M (99.68 %)
EPS:	HKD-0.190

FY	2021
Omsetning:	HKD4.31M
Bruttogevinst:	HKD4.17M (96.82 %)
EPS:	HKD-0.179

Financial Reports:

No articles found.

HBM Holdings Limited

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.